FARMINGDALE, N.Y., March 3, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, recently attended the 72nd Annual Scientific Conference of the American College of Foot and Ankle Surgeons where more than 200 podiatric professionals engaged in "hands-on" trials of Misonix's SonicOne O.R. Ultrasonic Surgical Debridement System. The conference took place at the Gaylord Palms Convention Center in Kissimmee, Florida from February 27, through March 1, 2014.
The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to treatment protocols, patient outcomes, and the delivery of cost-effective medical care at the medical institution level. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.
The American College of Foot and Ankle Surgeons (ACFAS) is a professional society of more than 7,000 foot and ankle surgeons. The conference attracted over 1,400 podiatric surgeons and represents one of the largest podiatric meetings in the United States. Visitors to the Misonix exhibit had an opportunity to perform hands on trials for the SonicOne O.R. system. Dr. Jason Seiter, President of the Arkansas Podiatric Medical Association and Chief of Podiatry at Sparks Regional Medical Center in Fort Smith, AR states, "Knowing that a number of my friends and colleagues around the country have recently brought the SonicOne system into their hospitals, I made a specific point to visit with the Misonix representatives to learn more about it. I was extremely impressed with what I was able to do with this technology and look forward to bringing SonicOne O.R. into my facilities as soon as possible. Misonix has a game changing surgical tool with SonicOne O.R. and this now represents a new standard of care for wound debridement."
Additionally, Dr. Timothy Syperek of Coast Podiatry and Wound Care in Jacksonville, Florida and Chief of Podiatry at St. Vincent's Healthcare offered, "Having had the opportunity to conduct a hands-on trial with the SonicOne O.R. at this year's meeting, I can see why so many of my colleagues now view the SonicOne O.R. as the tool of choice in wound care management. The ability to manage soft and hard tissue with the SonicOne O.R. is really a major improvement over the older water jet technologies that we once used. This technology is going to allow me to work faster, safer, and with better clinical outcomes for my patients. SonicOne O.R. now gives us a powerful tool to reduce biofilms in wounds, which are known to inhibit healing."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, comments, "We continue to be impressed with the market response to our SonicOne O.R. and this year's ACFAS meeting was simply outstanding. In excess of 200 people had the opportunity to trial the system and speak with our representatives. We continue to see more and more surgeons bringing their associates to the exhibit. This level of peer-to-peer endorsement is an important validation of our technology."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.